Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Consolidation Therapy in Chronic Lymphocytic Leukemia (CLL2i)
NCT00634881Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Nov 2003
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in chronic lymphocytic leukemia (CLL) (2 cohorts), sponsored by German CLL Study Group. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Started Nov 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00634881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634881.